Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study

American Journal of Epidemiology

Volumn 167, Issue 11, 2008, Pages 1375-1386

  Williams, Paige L ^a,b   Van Dyke, Russell ^c   Eagle, Michelle ^d   Smith, Dorothy ^e   Vincent, Carol ^f   Ciupak, Gregory ^g   Oleske, James ^h   Seage III, George R ^a,b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UMASS MEMORIAL MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Adolescent; Caregivers; Child; Cohort studies; HIV; Multicenter study; Patient participation; Proportional hazards model

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENCE; CHILD HEALTH; COHORT ANALYSIS; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR;

ACADEMIC ACHIEVEMENT; ARTICLE; CAREGIVER; CHILD; COHORT ANALYSIS; DEATH; EMPLOYMENT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EVENT; LIFE STRESS; MAJOR CLINICAL STUDY; MALE; MOTHER; RISK ASSESSMENT; SCHOOL; SOCIAL WORKER; SURVIVAL; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; LONGITUDINAL STUDIES; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

NORTH AMERICA; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 44449170460     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn072     Document Type: Article

References (31)

1. Conwell DS, Mosher A, Khan A, et al. Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22). Contemp Clin Trials 2007;28:288-94.
2. Brown DM, Thorne JE, Foster GL, et al. Factors affecting attrition in a longitudinal study of patients with AIDS. AIDS Care 2006;18:821-9.
3. Dudley J, Jin S, Hoover D, et al. The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol 1995;142:323-30.
4. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol 2001;154:563-73.
5. Matts JP, Launer CA, Nelson ET, et al. A graphical assessment of the potential impact of losses to follow-up on the validity of study results. The Terry Beirn Community Programs for Clinical Research on AIDS. Stat Med 1998;16:1943-54.
6. Hunt JR, White E. Retaining and tracking cohort study members. Epidemiol Rev 1998;20:57-70.
7. Neill KM, Chessa F. Recruitment and retention of women in nontherapeutic clinical trials. Appl Nurs Res 1998;3:148-51.
8. Orr PR, Blackhurst DW, Hawkins BS. Patient and clinic factors predictive of missed visits and inactive status in a multicenter clinical trial. Control Clin Trials 1992;13:40-9.
9. Morse EV, Simon PM, Besch CL, et al. Issues of recruitment, retention, and compliance in community-based clinical trials with traditionally underserved populations. Appl Nurs Res 1995;1:8-14.
10. Friedland DJ. Guide for assessing the validity of a study. In: Friedland DJ, ed. Evidence-based medicine: a framework for clinical practice. Stamford, CT: Appleton and Lange, 1998.
11. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-19.
12. Palta M, McHugh R. Planning the size of a cohort study in the presence of both losses to follow-up and non-compliance. J Chronic Dis 1980;33:501-12.
13. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001;153:619-27.
14. de Bruyn G, Hudgens MG, Sullivan PS, et al. Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 2005;39:499-501.
15. Amato DA. Selection of endpoints for assessment of treatment efficacy in an AIDS trial. In: Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials. New York, NY: Wiley, 1995.
16. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N Engl J Med 1999;341:198-203.
17. Grady A, Dickert N, Jawetz T, et al. An analysis of U.S. practices of paying research participants. Contemp Clin Trials 2005;26:365-75.
18. Iltis AS, DeVader S, Matsuo H. Payments to children and adolescents enrolled in research: a pilot study. Pediatrics 2006;118:1546-52.
19. Kimberly MB, Hoehn KS, Feudtner C, et al. Variation in standards of research compensation and child assent practices: a comparison of 69 institutional review board-approved informed permission and assent forms for 3 multicenter pediatric clinical trials. Pediatrics 2006;117:1706-11.
20. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
21. Brogly S, Williams P, Seage G III, et al. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 2005;293:2213-20.
22. Costagliola D, Mary-Krause M. Zidovudine in patients with HIV infection. (Letter). Ann Intern Med 1996;124:372.
23. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981;2:31-49.
24. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007;17:643-54.
25. Ioannidis JPA, Taha TE, Kumwenda N, et al. Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. Int J Epidemiol 1999;28:769-75.
26. Jacobson DL, Wu AW, Feinberg J, et al. Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. J Clin Epidemiol 2003;56:874-9.
27. Goldman AI, Holcomb R, Perry HM Jr, et al. Can dropout and other noncompliance be minimized in a clinical trial? Control Clin Trials 1982;3:75-89.
28. Cramer JA, Collins JF, Mattson RH. Can categorization of patient background be used to determine early termination in a clinical trial? Control Clin Trials 1988;9:47-63.
29. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006;118:e1745-57.
30. Poole WK, Perritt R, Shah KB, et al. A characterization of patient drop-outs in a cohort of HIV-positive homosexual/bisexual men and intravenous drug users. J Epidemiol Community Health 2001;55:66-7.
31. Bagley SJ, Reynolds WW, Nelson RB. Is a wage-payment model for research participation appropriate for children? Pediatrics 2007;119:46-51.